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Disease Severity in Respiratory 
Syncytial Virus Infection: Role of 
Viral and Host Factors
Julian P. Legg
Abstract
Respiratory syncytial virus (RSV) is not only a major cause of severe lower 
respiratory tract infection (LRTI) in infancy but is increasingly recognised as an 
important pathogen in later life. RSV infection is associated with a wide spec-
trum of disease ranging from asymptomatic infection to life-threatening bron-
chiolitis and pneumonia. Research has demonstrated that there exists a complex 
interplay between viral and host factors that determines the severity of disease 
following RSV infection. Several factors determine RSV virulence including the 
infective properties of individual strains and viral load (VL). Disease outcome 
from RSV infection is also impacted considerably by a variety of host factors 
with the host immune response increasingly recognised as pivotal. This chapter 
outlines our current understanding of these factors and provides an oversight of 
their relative importance.
Keywords: respiratory syncytial virus, disease severity, viral load, immunology, 
genotype
1. Introduction
Respiratory syncytial virus (RSV) has long been recognised as a cause of severe 
lower respiratory tract infection (LRTI) in early childhood with increasing evi-
dence of its role as an important pathogen in later life [1]. RSV has many intriguing 
features including its worldwide distribution, its capacity to cause severe disease in 
early childhood and its extended impact on respiratory health [2]. Consequently, 
RSV has been the focus of comprehensive study including host and viral determi-
nants of disease severity.
Serologic data has demonstrated that a high proportion of children (between 
50 and 70%) will be infected with RSV in the first year of life [3, 4]. Asymptomatic 
infection is infrequent during infancy with most infants developing clinical features 
of an upper respiratory tract infection alone [5]. Following an initial prodromal 
URTI phase, 25–40% of those infected will progress to develop signs and symp-
toms of bronchiolitis with tachypnoea and chest recession [5]. Bronchiolitis is 
usually a mild illness in most infants, but a small proportion (2–3%) will develop 
severe bronchiolitis necessitating hospitalisation [6]. It has been estimated that 
nearly 33.8 million new cases of RSV-associated LRTI occur worldwide in children 
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under 5 years of age leading to approximately 3.4 million hospitalizations annually 
[7]. Mortality from RSV infection in developed countries is rare during infancy 
although there are an estimated 66,000 and 239,000 yearly deaths in children 
younger than 5 in the developing world [7, 8].
The major clinical manifestation of RSV in older children and adults is upper 
respiratory tract illness (rhinitis and acute otitis media) although symptoms tend 
to last longer and there is an increased incidence of cough and wheeze compared to 
other respiratory viral infections [9, 10]. Immunity following RSV infection is only 
effective for a matter of months before the individual is once again susceptible to 
reinfection [11]. Consequently, reinfection occurs throughout life. LRTI is unusual 
although RSV accounts for a significant percentage (>4%) of community-acquired 
pneumonias during epidemics [12]. Elderly adults have an increased risk of lower 
respiratory tract involvement, with 30–40% of patients having auscultatory find-
ings on examination of the chest [13].
RSV is evidently associated with a wide spectrum of disease which has led 
to significant interest into those factors that determine the nature of the clinical 
response to infection. Host, viral and geographical factors interact to dictate the 
clinical outcome of any viral infection. The viral and host factors that influence the 
human response to RSV infection are the focus of this chapter.
2. Viral factors
2.1 The virus
Respiratory syncytial virus is a medium-sized (120–300 nm), enveloped, single-
stranded RNA virus of the Paramyxoviridae family that is a ubiquitous pathogen in 
all age groups. In 1956, it was first isolated from upper respiratory tract specimens 
collected from a chimpanzee with coryza [14], being subsequently recovered from 
two children in Baltimore with lower respiratory tract disease [15]. Its identification 
as a principal cause of bronchiolitis took a further 4 years [16].
2.2 Viral genome and proteins
RSV has a negative polarity RNA genome composed of 15,000 nucleotides with 
an estimated weight of 500 kDa. The non-segmented RNA genome encodes 10 units 
from which 11 proteins are translated. The RSV nucleocapsid core consists of the 
viral genomic RNA wrapped with N protein (called the N-RNA template), the major 
viral phosphoprotein, encoded by the P gene and the major subunit of the RNA-
dependent RNA polymerase, encoded by the L gene. The genome also encodes for 
two matrix proteins. The first matrix protein, M, is essential for RSV replication and 
passaging and plays a central role in virus assembly. The second matrix protein, M2, 
is localised within the nucleocapsid and has an essential role in the production of 
complete mRNA during replication. The NS1 and NS2 gene sequences encode for the 
so-called nonstructural proteins which have been shown to have multiple functions 
including abrogation of the cellular antiviral response and induction of interferon 
(IFN) transcription.
Three surface proteins are also encoded within the RSV genome, the fusion (F) 
protein, the G attachment (G) protein and the small hydrophobic (SH) protein. The 
F protein plays a central role in virus entry. It mediates fusion between the viral and 
cellular membrane, thereby allowing the nucleocapsid to enter the cytoplasm of 
the host cell. The G protein is essential for initial RSV attachment and interaction 
with the host cell and is important for in vivo replication. The SH protein is a short 
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integral membrane protein that is not essential for RSV replication in cell culture 
but is involved to some degree in RSV survival in vivo.
2.3 Viral load
The estimation of viral load (VL) has proved invaluable for predicting disease 
outcome in viral infections such as hepatitis C [17] and HIV [18]. The relationship 
between the quantity of RSV in respiratory tract specimens and disease severity has 
been the focus of multiple studies over the last 30 years. There has been significant 
variability in study findings to date, with some identifying a positive correlation 
between viral load and severity [19–21], while others have found no significant cor-
relation [22, 23] or an inverse relationship [24]. These disparate outcomes are likely 
related to the variable nature of the studies with significant differences in age range, 
enrolment criteria, quantification techniques (plaque assay vs. PCR) and timing 
of sample collection. The majority of studies have evaluated VL in hospitalised 
children only and at a single time point.
A number of recent studies have investigated the dynamics of viral load through 
the analysis of sequential specimens collected during the course of the illness. 
Garcia-Maurino et al. studied 150 children <2 years of age (39 outpatients and 
111 inpatients) over 2 successive winters [25]. Children who required hospitalisa-
tion had significantly lower VLs assessed using quantitative PCR on nasal swabs. 
Sequential VL evaluation (only evaluated in those hospitalised) demonstrated 
higher initial VLs and a faster VL decline in those requiring ward care only 
compared to those requiring PICU care. These findings are consistent with the 
results from a smaller study of 33 infants hospitalised with RSV bronchiolitis 
using nasosorption sampling of the upper airway [26]. Faster viral clearance was 
also associated with milder disease and a shorter length of stay in 219 children in 
Boston with RSV infection whose upper airway VL was assessed using plaque assay 
[27]. However, by contrast, higher VLs on day 3 of admission were associated with 
increased disease severity requiring PICU admission.
Studies to date highlight the complexity of the interaction between VL and 
disease severity. Further studies are required to clarify this relationship and 
should ideally analyse sequential specimens for changes in viral load in a tightly 
defined cohort of children and include both hospitalised and community infants 
with mild disease.
2.4 Genetic and antigenic variability
Through the application of monoclonal antibody technology, two major antigenic 
groups of RSV have been identified—the A and B subgroups [28]. Epidemiological 
studies have revealed that these groups have existed for over 40 years and have a 
worldwide distribution [28]. Both groups appear to circulate concurrently with 
geographical and temporal clustering frequently reported [29, 30]. The prevalence 
of each subgroup follows an irregular, alternating pattern with subgroup A pre-
dominating in most analyses [29]. The link between the major antigenic groups of 
RSV and disease severity is unclear. RSV-A has been associated with a more severe 
disease course in a number of studies [31–33], while others have identified no dif-
ference between the subgroups [34–37] or increased severity due to infection with 
RSV-B [38, 39]. While these inconsistent findings could result from differences in 
study design and geography, the presence of varying RSV genotypes is likely to be a 
significant confounding factor.
The RSV genome demonstrates significantly more variability than previously 
understood [1].
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The G protein has been demonstrated as the greatest source of intragroup 
variability with nucleotide differences of up to 20% [40]. These differences reside 
predominantly within two variable regions that flank a relatively conserved central 
ectodomain of the G protein gene.
The single-stranded, non-segmented nature of the RSV genome precludes the 
genetic rearrangements that typify the dramatic antigenic shifts of the influenza 
virus [41]. However, there is a considerable potential for genomic mutation given 
the inability of RNA polymerase to proof-read during replication of the genome. 
This provides an opportunity for antigenic drift to occur under the influence of 
selective pressures from the environment. The current variability of the G protein 
between RSV strains may therefore be explained by the progressive accumulation of 
change together with survival and extinction of particular genotypes [42].
Prior to whole-genome sequencing, genetic studies have assessed strain vari-
ability within the two major groups primarily through analysis of the G protein gene 
[42, 43]. Subsequent phylogenetic analyses have identified multiple lineages within 
both group A and group B viruses with marked similarities observed between 
strains from different locations and time periods [29, 42, 44]. This has led to the 
recent subclassification of RSV into 14 RSV-A genotypes and 24 RSV-B genotypes 
[45]. Several distinct RSV strains appear to cocirculate within an individual com-
munity during each annual epidemic with the predominant strain varying year 
to year [44, 46]. Multiple elements appear to determine prevailing annual strains 
including herd and maternal immunity, changes in social contacts and migration as 
well as viral factors [29, 47–49].
RSV’s capacity for genomic mutation is exemplified by the emergence of two 
novel genotypes, RSV-B BA and RSV-A ON1 genotypes. In 1999, the BA genotype 
was first detected in Buenos Aires, Argentina [50], and has since spread gradually 
and sequentially throughout the world [51], becoming the predominant group B gen-
otype, and even replacing all previous circulating RSV-B genotypes in some regions 
[52, 53]. Subsequently, the RSV-A genotype ON1 was identified in Ontario, Canada, 
in 2010 [54] and has rapidly spread worldwide [55]. Both genotypes demonstrate a 
60–72 base pair duplication in the G protein gene which may change the antigenic 
properties of the protein enabling evasion of the host immune response [50, 56].
The possibility that distinct RSV genotypes may have differing virulence has led to 
several studies in this area. Much interest has concerned the possible association of the 
ON1 genotype with less severe disease. Panayiotou et al. first described this association 
in 99 children <2 years of age hospitalised with a RSV respiratory tract infection over 
3 successive Cypriot winters [39]. The ON1 genotype was associated with significantly 
milder illness (as determined by a clinical severity score) than either GA1 (RSV-A) or 
BA (RSV-B) genotypes. This finding has also been observed in a number of subsequent 
studies including a recent study of 329 infants with a clinical diagnosis of bronchiolitis 
and infected with RSV alone [57, 58]. Infants with the NA1 genotype had a milder 
clinical course both in terms of clinical severity scores and need for admission to 
PICU. Conversely, other studies have reported a similar clinical course with different 
genotypes [36, 59] or that genotype ON1 was associated with more severe disease in a 
group of Vietnamese children hospitalised with signs of LRTI [60].
Once again, the lack of a consistent association between genotype and dis-
ease severity is presumably due to variable study design and geographic factors. 
However, other factors should be considered. All studies to date have encompassed 
multiple years to enable analysis of different viral strains as the dominant genotype 
varies year to year. This inherently introduces a significant confounder with changes 
between years in staff, clinical practice, herd immunity, etc. In addition, there is 
increasing evidence of virulence factors encoded in regions of the genome outside 
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the G protein hypervariable region that has been traditionally used for genotyping. 
Studies in the mouse model have demonstrated that specific sequences within the 
conserved central domain of the G protein influence RSV binding to the chemokine 
receptor CX3CR1 impacting host response [61] and sequences contained in the F 
protein are associated with significant differences in disease severity [62].
The possibility of different RSV genotypes having distinct infective properties 
is an attractive explanation for the diverse severity of RSV disease which merits 
further study. It is apparent that the interaction between RSV strain and disease is 
complex. Whole-genome sequencing perhaps provides the best future opportunity 
to further our understanding [1].
3. Host factors
3.1 Predisposing health factors
Pre-existing illness and disease have been long recognised as having a significant 
impact on the severity of RSV disease. RSV infection in children with congenital 
immunodeficiency (particularly of cell-mediated immunity) is associated with 
a more severe clinical course [63], and individuals requiring immunosuppres-
sive therapy (such as haemopoietic cell transplant (HCT) recipients and patients 
undergoing chemotherapy) also experience more sever disease. Following HCT, 
RSV infection is associated with significant morbidity, including complications 
such as late graft dysfunction and bronchiolitis obliterans syndrome. Mortality rates 
range from 7 to 83% depending on a number of risk factors including lymphopenia 
and high-dose total body irradiation [64–66]. Adult patients with leukaemia are 
particularly vulnerable to RSV infection with reported mortality rates between 20 
and 85% in those developing pneumonia [67] although children with leukaemia 
appear to follow a more benign clinical course [68].
Pre-existing cardiopulmonary disease has a significant impact on the clinical 
response to RSV infection. Underlying congenital heart disease in infants and 
children has long been recognised to be associated with more severe outcomes from 
RSV, including more frequent hospitalisation, longer lengths of stay and higher 
rates of intensive care unit admission [69]. Similarly, children with bronchopul-
monary disease have markedly increased morbidity and mortality due to RSV [70]. 
Adults with underlying cardiac and pulmonary diseases are also prone to severe 
respiratory illnesses with RSV infection [71]. Adults with chronic obstructive pul-
monary disease are particularly vulnerable to RSV infection with a high incidence 
of lower respiratory tract disease and frequent hospitalisation [71].
The impact of RSV at the extremes of age is significant. Premature birth is a 
significant risk factor for severe RSV disease; those born at less than 32 weeks of 
gestational age have approximately double the hospitalisation risk of infants born 
later [72]. Incomplete immunological and pulmonary maturation and reduced 
transfer of maternal antibodies are all thought to contribute to this increased risk. 
The burden in the elderly is also significant with evidence that the impact is similar 
to that of non-pandemic influenza, both in the community and in nursing homes 
[73]. RSV outbreaks in nursing homes have been well documented, studies report-
ing infection rates of over 10% with pneumonia in up to 55% of those affected 
and mortality rates of up to 20% [73]. A recent prospective, international study 
detected RSV in over 7% of moderate to severe acute respiratory episodes observed 
in elderly adults living at home and found that the incidence of RSV infection 
increased with age [13].
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3.2 Predisposing airway geometry
The potential impact of reduced premorbid lung function on the response to 
a subsequent RSV infection has been of interest for many years. Two initial stud-
ies published in 1995 demonstrated that a reduced maximum expiratory flow at 
functional residual capacity (VmaxFRC—believed to reflect the size of intrapulmo-
nary airways) measured in infancy before any lower respiratory tract illness was 
associated with subsequent virus-associated wheeze [74, 75]. Subsequently, a large 
prospective study of 2133 infants who had neonatal lung function performed found 
that those subsequently hospitalised with RSV infection had significantly decreased 
lung function compared to those with RSV infection managed in the community 
[76]. These data together would suggest that congenitally smaller airways may 
predispose infants to more severe RSV disease.
3.3 Host immune factors
The immune response to infection can be divided into two arms:
1. Innate immunity—this refers to nonspecific defence mechanisms that acti-
vate immediately or within hours of exposure to an infecting organism. The 
efficacy of these mechanisms does not rely on clonal expansion.
2. Adaptive immunity—the adaptive immune response relies on the clonal 
expansion of antigen-specific lymphocytes and can take several days to 
complete. A principal feature of the adaptive immune response is the genera-
tion of immunological memory enabling a more rapid and effective response 
to pathogens that have been previously encountered.
3.3.1 Innate immunity
The innate immune response to RSV infection consists of a coordinated response 
incorporating a variety of cell types and their products. The character of this 
response is a critical determinant of the outcome of infection. A slow, weak or 
inappropriate response will result in delayed viral clearance enabling the virus to 
spread to the lower airway producing enhanced pathology. An inappropriate innate 
response will also have a direct impact on the nature and efficacy of the adaptive 
immune response.
The importance of innate immunity is highlighted by genetic association studies 
which have identified the strongest associations with severe disease due to polymor-
phisms of the innate immune system at both the allele and genotype level [77, 78].
3.3.1.1 Toll-like receptors
Type I interferons (IFN-I, α/β) are an important part of the innate immune 
response to viral infection. Various cell intrinsic pattern recognition receptors 
(PRRs) including the Toll-like receptors (TLR) recognise RSV as foreign and 
potentially dangerous. This leads to the activation of key transcription factors 
including interferon regulatory factors which regulate the expression of IFN-I 
and pro-inflammatory cytokines [79]. IFN-I upregulates transcription of multiple 
interferon-stimulated genes (ISGs) via the IFN-I receptor, which interfere with viral 
replication, thus facilitating viral clearance.
TLR polymorphisms have been widely studied for their potential associa-
tion with severe RSV disease. Tal et al. identified an overrepresentation of a 
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heterozygous genotype in two TLR4 mutations (Asp299Gly and Thr399Ile) among 
a group of infants necessitating hospitalisation compared to a community-managed 
group [80]. Similarly, the same mutations were significantly associated with 
hospitalisation in a group of primarily premature infants with symptomatic RSV 
infection [81]. However, subsequent studies have failed to confirm these findings 
[82, 83] although one study has identified significant variability between different 
RSV epidemics in the genetic risk of severe disease associated with these polymor-
phisms [83]. This highlights the complex interplay between host genetic factors and 
the predominant circulating viral strain.
3.3.1.2 Surfactant proteins
The surfactant proteins (SPs) primarily reduce surface tension of the alveoli to 
prevent lung collapse but also make a significant contribution to innate immunity. 
In vitro, SP-A enhances uptake of RSV by macrophages, reduces RSV-induced 
suppression of host cell tumour necrosis factor-α (TNF-α) and augments the 
production of anti-inflammatory interleukin-10 (IL-10) [84]. SP-D-deficient mice 
develop severe disease on exposure to RSV and have delayed viral clearance [85]. 
Studies on ventilated infants with RSV infection have demonstrated low surfactant 
activity and reduced levels of SP-A, SP-B and SP-D compared to controls [86, 87]. In 
addition, genetic analyses have identified certain polymorphisms of the surfactant 
proteins that are associated with severe disease in RSV-infected infants [88, 89].
3.3.1.3 Inflammatory mediators
The initial contact between RSV and the host is typically at the nasal epithelium. 
The epithelial surfaces form a physical barrier that is impermeable to most infectious 
agents, acting as the first line of defence against invading organisms. In response to 
contact with RSV, the epithelium also releases a variety of pro-inflammatory media-
tors and cytokines that play an important part in the innate immune response. A 
number of in vitro studies have demonstrated the production of IL-1; IL-6; IL-8; 
tumour necrosis factor-α; regulated upon activation, normal T-cell expressed and 
presumably secreted (RANTES); and CXCL8 by RSV-infected primary airway 
epithelial cell cultures [90–92]. Macrophages and neutrophils are important phago-
cytes but also produce a wide range of immunological mediators, including MIP-1α, 
RANTES, IL-1, IL-6 and IL-8, when infected with RSV in vitro [93, 94]. Such 
mediators have a significant impact on both early inflammation as well as subsequent 
immunological responses. For example, IL-8 is chemotactic for neutrophils as well 
as being a potent activator. Similarly, MIP-1α and RANTES activate both monocytes 
and eosinophils as well as being potent CD4+ T-cell chemoattractants.
Respiratory secretions from infants and children infected with RSV have been 
found to contain many of these mediators [38, 95–97]. Some studies have also 
identified correlates between certain inflammatory mediator concentrations and 
disease severity. Higher levels of IL-8 have been identified in severe disease with a 
strong correlation with oxygen requirement and need for ventilation [96, 98]. Nasal 
concentrations of MIP-1α are significantly increased in children with RSV bron-
chiolitis that require oxygen therapy [99] and in RSV-infected adults that require 
hospitalisation [100].
There has been much interest in the contribution of RANTES, a potent 
chemoattractant for eosinophils, T cells and monocytes, to the pathogenesis of 
RSV disease. RANTES levels in tracheal aspirates have been found to correlate 
inversely with markers of disease severity in RSV bronchiolitis [95], and the 
ratio of TNF-receptor to RANTES in nasopharyngeal aspirates is significantly 
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raised in infants with severe RSV disease [101]. The potential protective impact 
of RANTES has been further explored through analysis of promoter and intronic 
polymorphisms in the RANTES gene. Certain polymorphisms (e.g., −403 G/A) 
have been associated with reduced disease severity and greater production of 
RANTES [102, 103].
3.3.1.4 Eosinophils
Eosinophils have been traditionally regarded as important in the innate immune 
response to helminthic infection although several studies have suggested their pos-
sible contribution to RSV immunity. Eosinophil cationic protein (ECP), a cytotoxic 
protein released with eosinophil activation, is found in nasal lavage fluid and serum 
from children with severe RSV infection [104]. ECP levels in nasopharyngeal secre-
tions have been found to correlate with disease severity [105, 106] suggesting a role 
for the eosinophil in the pathogenesis of RSV disease.
3.3.2 Adaptive immunity
3.3.2.1 Humoral immunity
The developing foetus acquires maternal IgG antibodies to RSV through the 
placenta actively. The transfer rate gradually increases from 30 weeks of gestation 
to a maximum between 38 and 40 weeks. Following birth, levels of neutralising 
antibody slowly diminish with a mean half-life of 26 days [107]. The quantity of 
antibody transferred is important in protecting infants against infection; higher 
specific antibody titres are associated with milder disease following RSV infection 
[108]. Infants also acquire antibodies from the mother through breast feeding with 
breast fed infants having significantly reduced oxygen requirement and length of 
stay following hospitalisation with RSV bronchiolitis [109].
There is considerable variability in the humoral response of infants to pri-
mary infection. During the first year of life, there is rapid maturation of the 
immune system, and this may account for much of this variability. In the first 
6 months of life, the serum IgA response is greater than that of IgG [110]. In 
older children, there is a predominant rise in IgG levels with IgG1 and IgG3 
subclasses accounting for the major part of this response [110], whereas IgG1 
and IgG2 subclasses form the bulk of the adult response [111]. As well as these 
qualitative differences in antibody response with age, there is also quantitative 
variation with generally very low titres of antibody produced in early infancy. 
The antibody titres against both the F and G surface proteins of RSV in infancy 
are 10 to 12 times lower than those observed in children over 12 months of age 
[112]. This blunted response appears to be caused by a combination of factors 
including the presence of residual maternal antibody and immaturity of the 
immune system [113].
Murine studies have demonstrated that the humoral response is an important 
factor in RSV disease severity. B-cell-depleted mice, which consequently have no 
antibody response to infection, experience greater illness on primary RSV infec-
tion [114]. Similarly, higher neutralising antibody titres in children are associated 
with a lower incidence of severe lower respiratory tract disease once infected 
with RSV. Clinical severity scores inversely correlate with antibody titres to the F 
protein in infants with RSV infection [115], and therapeutic trials of polyclonal 
and monoclonal antibodies have demonstrated reduced disease severity in treated 
infants [116, 117].
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3.3.2.2 Cell-mediated immunity
The cellular arm of the adaptive immune response is orchestrated primarily 
by cytotoxic T lymphocytes (CTLs) and T-helper (Th) lymphocytes. Cell-
mediated immunity is extremely important for the eradication and abrogation 
of the clinical response to RSV infection as highlighted by the severe impact of 
infection in individuals with severe congenital/acquired impairment of cellular 
immunity [63, 118].
3.3.2.2.1 Cytotoxic T lymphocytes (CD8+ T cells)
CTLs are pivotal for the control of many intracellular pathogens and have the 
capacity to differentiate into long-lived memory CTLs which provide a rapid, robust 
response to subsequent infection. CTLs have been found to have an important 
role in clearing RSV during animal studies. Mice that have been rendered athymic 
are unable to produce a CTL response to RSV infection and become chronically 
infected. Clearance of the virus can be subsequently achieved by injecting the mice 
with primed RSV-specific CTLs [119]. There is also some evidence that CTLs can 
contribute to severe disease if produced in large numbers [120].
Unfortunately, the role of CTLs in human RSV infection has been little studied 
largely due to the relatively modest RSV-specific T-cell responses observed in the 
blood and the low numbers of RSV-specific T-cell memory cells present between 
infections. Using HLA tetrameric staining, RSV-specific CD8+ T cells were analysed 
in bronchoalveolar lavage fluid and blood specimens from infants requiring ventila-
tory support for RSV bronchiolitis. RSV-specific T-cell numbers peaked in blood 
around days 9–12 (at the time of recovery), and there was no correlation between 
cell numbers and parameters of disease severity [121]. A similar pattern is observed 
in experimental infection of adult volunteers where antigen-specific CD8+ T-cell 
numbers peak 10 days after initial infection at approximately the same time as a 
fall in viral load and resolution of symptoms [122]. This would perhaps suggest an 
important contribution to viral clearance although the impact of CTLs on disease 
severity in man remains undefined.
3.3.2.2.2 T-helper lymphocytes (CD4+ T cells)
CD4+ T cells recognise antigens presented on MHC class II molecules, which are 
found on antigen-presenting cells. They respond by releasing cytokines which play a 
major role in instigating and shaping adaptive immune responses. The cytokines pro-
duced have been used to differentiate these cells into the two major classes of effector 
T cell—T helper (Th) 1 (producing type 1 cytokines) and Th2 (producing type 2 
cytokines) [123]. In general, type 1 cytokines (such as interferon-gamma (IFN-γ) 
and IL-12) favour the development of a strong cellular immune response and are an 
important component of an effective response to intracellular pathogens including 
viruses. Type 2 cytokines (such as IL-4 and IL-5) favour a strong humoral response to 
infection by promoting B-cell proliferation and increased production of antibodies. 
Type 2 cytokines also mediate allergic responses. Cross regulation occurs between the 
two responses, and responses deviated toward type 2 or away from type 1 are associ-
ated with more severe disease in several infectious disease model [124, 125].
Indirect evidence suggests that T-helper lymphocytes have a significant role in RSV 
disease with CD4+ T cells constituting the largest lymphocyte population in bron-
choalveolar lavage fluid obtained from infants ventilated for RSV bronchiolitis [126]. 
Subsequent studies have focussed on the exact nature of this CD4+ T-cell response.
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Murine studies have demonstrated that prior sensitisation to RSV surface 
proteins followed 3 weeks later by RSV infection can induce polarised cyto-
kine responses which follow broad type 1 and type 2 repertoires [127]. Type 2 
responses were associated with enhanced disease characterised by pulmonary 
haemorrhage and eosinophilia while those with type 1 responses had reduced 
immunopathology and enhanced viral clearance [128]. A type 2 cytokine response 
also correlates with quantitated pulmonary pathology following primary RSV 
infection of BALB/c mice [129].
Multiple human studies have examined type 1 and type 2 immune responses to 
RSV and have largely identified a similar predominance of type 2 cytokines in those 
with more severe disease. Type 1 cytokines (including IFN-γ and TNF-α) are increased 
in the circulation, the nose and lung during an RSV LRTI [96, 130, 131]. Lower IFN-γ 
levels are associated with increased severity scores, hypoxia and need for ventilation 
[97, 131–134]. Type 2 cytokines (including IL-4, IL-10 and IL-13) are also increased 
in the blood, nose and lung during RSV LRTI [95, 132, 135]. However, higher type 2 
cytokine levels are generally associated with more severe disease. Systemic IL-10 levels 
correlate with disease severity in RSV LRTI [136, 137] although respiratory tract IL-10 
levels would appear to be associated with milder disease features [95].
Multiple studies have also evaluated the type 1/type 2 immune balance through 
the quantification of cytokine ratio. The ratio of IL-4 to IFN-γ is raised both 
systemically and in the respiratory tract in patients with bronchiolitis that require 
oxygen therapy suggesting a skew towards type 2 responses [138, 139]. Similarly, 
IL-4:IFN-γ and IL-10:IL-12 ratios are raised in nasal lavage obtained from infants 
with RSV who develop bronchiolitis compared to those that develop signs of an 
URTI only [23], and type 2 cytokines predominate in nasopharyngeal specimens 
from children with hypoxic RSV LRTI [96].
Overall, current evidence would support a bias towards a type 2 T-helper cell 
response in severe RSV infection. Further studies are, however, required to confirm 
these findings and would ideally analyse prospectively the cytokine response both 
systemically and within the airway. Such studies should, also, examine both chil-
dren and adults with RSV infection using relevant study groups (URTI, LRTI) and 
strictly control for potential confounding factors such as sampling times (relative to 
infection onset) and age differences between groups.
3.3.2.2.3 Regulatory T cells
Regulatory T cells (Tregs) are immunoregulating cells that maintain the immu-
nological equilibrium by controlling effector T-cell activation and hence preventing 
tissue damage during the immune response to infections [140]. Animal studies 
in Treg-depleted mice have highlighted their importance. RSV infection of Treg-
depleted mice results in severe disease with a significantly elevated viral load and an 
exuberant cytotoxic T-cell response highlighting the importance of Tregs for both 
viral clearance and control of the RSV-specific T-cell response [141]. A recent study 
of infants with severe bronchiolitis demonstrated a prolonged reduction in Tregs 
in these patients compared to a similarly aged, healthy control group [142]. While 
intriguing, further studies are required to confirm this finding and to clarify the 
role of Tregs in severity of RSV disease.
4. Conclusion
The broad spectrum of disease due to RSV infection likely represents a complex 
interplay between multiple viral and host factors. Despite significant research in 
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this area, our understanding of the relative importance of each factor is limited 
although recent studies that have examined multiple components of the virus-host 
interaction have provided some insight. Individual viral strains have differing 
infective properties which primarily determine RSV virulence alongside other fac-
tors such as viral load. The host immune response is increasingly recognised as an 
important determinant of disease severity. Other host factors including underlying 
immunological/cardiopulmonary disease and small airway geometry in infancy also 
appear to have an important impact.
Each year 2–3% of all infants require hospitalisation due to RSV outbreaks [6]. 
These epidemics result in substantial healthcare costs with direct medical costs for 
children <5 years old amounting to over $600 million in the United States alone 
[143]. Despite the substantial impact of RSV, advances in effective prevention and 
treatment have been slow. Future studies that consider fully the contribution of 
both viral and host factors in the pathogenesis of severe disease will undoubtedly 
facilitate the development of effective therapies.
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